BACKGROUND: Concurrent medical comorbidity influences the accurate diagnosis and treatment of major depressive disorder (MDD). OBJECTIVE: The objective of this study was to validate previous findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study using a confirmation analysis in a previously unanalyzed cohort. DESIGN: Baseline cross-sectional case-control study of patients enrolling in a prospective randomized multistage treatment study of nonpsychotic MDD. SETTING: Fourteen regional U.S. centers representing 18 primary care and 23 psychiatric practices. PARTICIPANTS: 2541 outpatients with DSM-IV nonpsychotic MDD. MEASUREMENTS: Sociodemographic status, medical illness ratings, psychiatric status, quality of life, and DSM-IV depression symptom ratings. RESULTS: The prevalence of significant general medical comorbidity in this population was 50.0% (95% CI = 48.1% to 52.0%), consistent with findings reported for the first cohort. Concurrent significant medical comorbidity was associated with older age, lower income, unemployment, limited education, and longer duration of index depressive episode. The group with significant medical comorbidity reported higher rates of somatic symptoms, gastrointestinal symptoms, sympathetic arousal, and leaden paralysis. These results were generally consistent between the 2 cohorts from STAR*D. CONCLUSIONS: Major depressive disorder with concurrent general medical conditions is associated with a specific sociodemographic profile and pattern of depressive symptoms. This association has implications for diagnosis and clinical care.
BACKGROUND: Concurrent medical comorbidity influences the accurate diagnosis and treatment of major depressive disorder (MDD). OBJECTIVE: The objective of this study was to validate previous findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study using a confirmation analysis in a previously unanalyzed cohort. DESIGN: Baseline cross-sectional case-control study of patients enrolling in a prospective randomized multistage treatment study of nonpsychotic MDD. SETTING: Fourteen regional U.S. centers representing 18 primary care and 23 psychiatric practices. PARTICIPANTS: 2541 outpatients with DSM-IV nonpsychotic MDD. MEASUREMENTS: Sociodemographic status, medical illness ratings, psychiatric status, quality of life, and DSM-IV depression symptom ratings. RESULTS: The prevalence of significant general medical comorbidity in this population was 50.0% (95% CI = 48.1% to 52.0%), consistent with findings reported for the first cohort. Concurrent significant medical comorbidity was associated with older age, lower income, unemployment, limited education, and longer duration of index depressive episode. The group with significant medical comorbidity reported higher rates of somatic symptoms, gastrointestinal symptoms, sympathetic arousal, and leaden paralysis. These results were generally consistent between the 2 cohorts from STAR*D. CONCLUSIONS:Major depressive disorder with concurrent general medical conditions is associated with a specific sociodemographic profile and pattern of depressive symptoms. This association has implications for diagnosis and clinical care.
Authors: Dwight L Evans; Dennis S Charney; Lydia Lewis; Robert N Golden; Jack M Gorman; K Ranga Rama Krishnan; Charles B Nemeroff; J Douglas Bremner; Robert M Carney; James C Coyne; Mahlon R Delong; Nancy Frasure-Smith; Alexander H Glassman; Philip W Gold; Igor Grant; Lisa Gwyther; Gail Ironson; Robert L Johnson; Andres M Kanner; Wayne J Katon; Peter G Kaufmann; Francis J Keefe; Terence Ketter; Thomas P Laughren; Jane Leserman; Constantine G Lyketsos; William M McDonald; Bruce S McEwen; Andrew H Miller; Dominique Musselman; Christopher O'Connor; John M Petitto; Bruce G Pollock; Robert G Robinson; Steven P Roose; Julia Rowland; Yvette Sheline; David S Sheps; Gregory Simon; David Spiegel; Albert Stunkard; Trey Sunderland; Paul Tibbits; William J Valvo Journal: Biol Psychiatry Date: 2005-08-01 Impact factor: 13.382
Authors: Ronald C Kessler; Olga Demler; Richard G Frank; Mark Olfson; Harold Alan Pincus; Ellen E Walters; Philip Wang; Kenneth B Wells; Alan M Zaslavsky Journal: N Engl J Med Date: 2005-06-16 Impact factor: 91.245
Authors: William R Yates; Jeff Mitchell; A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Diane Warden; Robert B Hauger; Maurizio Fava; Bradley N Gaynes; Mustafa M Husain; Charlene Bryan Journal: Gen Hosp Psychiatry Date: 2004 Nov-Dec Impact factor: 3.238
Authors: Maurizio Fava; A John Rush; Madhukar H Trivedi; Andrew A Nierenberg; Michael E Thase; Harold A Sackeim; Frederic M Quitkin; Steven Wisniewski; Philip W Lavori; Jerrold F Rosenbaum; David J Kupfer Journal: Psychiatr Clin North Am Date: 2003-06
Authors: W W IsHak; J Mirocha; D James; G Tobia; J Vilhauer; H Fakhry; S Pi; E Hanson; R Nashawati; E D Peselow; R M Cohen Journal: Acta Psychiatr Scand Date: 2014-06-23 Impact factor: 6.392
Authors: Hailey W Bulls; Mary K Lynch; Megan E Petrov; Ethan W Gossett; Michael A Owens; Sarah C Terry; Kate M Wesson-Sides; Burel R Goodin Journal: Ann Behav Med Date: 2017-10
Authors: David W Morris; Nitin Budhwar; Mustafa Husain; Stephen R Wisniewski; Benji T Kurian; James F Luther; Kevin Kerber; A John Rush; Madhukar H Trivedi Journal: Ann Fam Med Date: 2012 Jan-Feb Impact factor: 5.166
Authors: L Miriam Dickinson; W Perry Dickinson; Kathryn Rost; Frank DeGruy; Caroline Emsermann; Desireé Froshaug; Paul A Nutting; Lisa Meredith Journal: J Gen Intern Med Date: 2008-08-05 Impact factor: 5.128
Authors: Waguih William IsHak; Alexander J Steiner; Anna Klimowicz; Kaitlyn Kauzor; Jonathan Dang; Brigitte Vanle; Christina Elzahaby; Mark Reid; Lekeisha Sumner; Itai Danovitch Journal: Psychopharmacol Bull Date: 2018-01-15